We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
MiMedx is suing wound-treatment competitor Osiris Therapeutics, accusing it of falsely claiming in a press release that its biologic is superior to MiMedx’s product. Read More
Amgen is suing generics maker Sandoz, claiming that Sandoz’s attempts to market a biosimilar for the blockbuster bone marrow drug Neulasta infringes on two of its patents for the drug. Read More
A planned settlement between Aegerion Pharmaceuticals and federal officials will require the company to shell out $40 million and plead guilty to two misdemeanor violations of the FD&C Act, the company disclosed Friday. Read More
The UK’s National Institute for Health and Care Excellence says it will not recommend Bristol-Myers Squibb’s Opdivo, casting doubt on the drug’s cost-effectiveness for people with locally advanced or metastatic non-squamous, non-small-cell lung cancer after chemotherapy. Read More
Clovis Oncology is stopping development of its lung cancer candidate rociletinib after the FDA warned the company of a potential complete response letter. Read More
To bridge the gulf between the promise of biosimilars on drug pricing and the reality, payors should incentivize biosimilar utilization, a new report states. Read More
UK regulators have fined Pfizer $14,000 for failing to explain a questionable claim meant to justify price increases on the generic seizure medication Epanutin. Read More